Acorda Therapeutics (ACOR) is up due to the positive opinion on Marketing Authorization Application for its MS drug Ampyra in Europe. This approval for Acorda Therapeutics was expected. The big move in Acorda is unwarranted.
We are short selling in the strength now with an average price $32.98 and will add if the stock goes higher.
As a full disclosure, this alert was earlier published in ZYX Short Sell Change Alert — Real Time Feed. For stops and targets please see ZYX Short Sell Change Alert.
